

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE****Applicants Docket Number:**  
**ST01001 US NP****Applicants:**  
**Maillet, et al****Serial No.**  
**10/040,370****Filing Date:**  
**January 9, 2002****Title of Invention:****Chemical Derivatives And Their Application as Antitelomerase Agents****CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 872-9306, on

Date of Deposit

7-12-04

Printed Name of Person Signing Certificate

Maribel Mendez

Signature

Maribel Mendez

**Total Number of Pages Sent: 28****Attorney: Balam Gupta****Group Art Unit: 1624**  
**Examiner: Venkataraman**  
**Balasubramanian****OFFICIAL****TO: Mail Stop AF**  
**Commissioner for Patents**  
**P. O. Box 1450**  
**Alexandria, VA 22313-1450****RECEIVED**  
**CENTRAL FAX CENTER**

JUL 12 2004

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

☒ **Amendment, 37 CFR § 1.121 and Reply Pursuant to 37 C.F.R. § 1.116 (25 pgs.)**☐ **Fee Transmittal**☐ **Charge deposit account, in duplicate**☐ **Petition under 37 CFR \_\_\_\_\_**☒ **Extension of Time Petition (1 pg.)**☐ **Other \_\_\_\_\_**☐ **Issue Fee Transmittal & Advance Order**☒ **Other Notice of Appeal From The Primary Examiner To The Board Of Patent Appeals And Interferences (1 pg.)**☐ **Maintenance Fee Transmittal****Receipt Confirmed:****Signed****Dated**

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

**PATENT****Docket No.: ST01001 US NP****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re Application of  
Mailliet et al****Examiner: Venkataraman  
Balasubramanian****Serial No.: 10/040,370****Art Unit: 1624****Filed: January 09, 2002****Title: Chemical Derivatives and Their Application  
as Antitelomerase Agents****TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, at (703) 872-9306 on

7-12-04  
Date of transmission

Signature

**RECEIVED****CENTRAL FAX CENTER****JUL 12 2004**

Mail Stop: AF  
Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

**AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY  
PURSUANT TO 37 C.F.R. § 1.116****Sir:**

This is a Rule 116 Amendment in the above-identified patent application in response to the Office Action, paper no. 20040208, dated, February 11, 2004, having a response due by, May 11, 2004. A petition for two-month extension of time is concurrently filed herewith, thus this response is timely filed by July 12, 2004. It is respectfully requested that the following amendments and remarks be entered in this case.

***Request to Change Docket Number***

Applicants respectfully submit that the docket number used in the instant case has been changed from "03806.0533" to "ST01001 US NP". Accordingly, Applicants respectfully request the Examiner to enter this change into the record and to use the new docket number in all of the future Office Actions in this case.

ST01001 US NP

-1 of 25-